C15H17FN 2 O4, monoclinic, P21/c (no. 14), a = 12.4266(11) Å, b = 6.6865(5) Å, c = 17.1510(15) Å,
. The title compound (3.0 mg) was dissolved in DCM in a NMR tube and the tube was covered loosely with cap to enable the solvent to slowly evaporate at ambient conditions. Crystals suitable for X-ray diffraction formed over a period of 7 days.
Experimental details
All hydrogen atoms were placed in idealised positions and refined using a riding model with U iso assigned 1.2 or 1.5 times Ueq of their parent atoms and the C-H bond distances constrained between 0.95 and 1.00 Å. The final conventional R factor is 0.0422.
Discussion
In the past decade oxazolidonone compounds have attracted much attention because of their biologically properties [6] [7] [8] [9] . They are totally synthetic antibacterial agents with a novel mechanism of action involving the inhibition of bacterial protein synthesis at a very early stage, thus disrupting chain initiation [9, 10] . Linezolid and tedizolid are the only members of oxazolidonone compounds that are in clinical use for treatment of bacterial infection in humans [11] . Herein, we report the single crystal structure and packing analysis of a linezolid analogue, C15H17FN 2 O4. The title compound can be considered to be flexible as the conformation of the five membered oxazoline and six membered morpholine 
